OrbiMed Capital GP VI LLC
CIK 1682115 · last filed 2025-08-12
OrbiMed Capital GP VI LLC is a corporate insider who has filed 42 SEC Form 4 insider transactions across 19 companies since 2017. The most recent filing, for TSBX, was dated Aug 12, 2025. Across all open-market trades the lifetime net is −$105.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $793.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$793.80M
19
42
-$105.94M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Turnstone Biologics Corp. (TSBX) Delisted | Director | 0 | $0.35 | $0 | $0 | 1 | 2025-08-12 |
| NPCE | 10%+ Owner | 3,272,199 | $15.31 | $50.10M | $2.51M | 4 | 2025-05-16 |
| CMPX | Director | 15,219,994 | $2.04 | $31.05M | -$17.04M | 1 | 2025-04-11 |
| IRON | Director | 776,844 | $74.65 | $57.99M | -$67.86M | 1 | 2025-03-12 |
| SPRY | Director | 8,019,187 | $5.67 | $45.47M | -$25.19M | 2 | 2024-08-23 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | $4.00M | 2 | 2024-05-20 |
| EWTX | Director | 14,436,497 | $40.35 | $582.51M | $47.25M | 3 | 2024-01-25 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 13,107 | $17.16 | $224.9K | $0 | 1 | 2023-09-21 |
| Verona Pharma plc (VRNA) Delisted | Director | 4,180,691 | $106.91 | $446.96M | -$19.88M | 1 | 2023-05-15 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 5,328,328 | $5.67 | $30.21M | $47.01M | 2 | 2022-11-29 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | 10%+ Owner | 5,629,842 | $46.99 | $264.55M | -$242.57M | 8 | 2022-09-14 |
| ORIC | Director | 2,240,440 | $11.91 | $26.68M | -$1.28M | 4 | 2021-03-31 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 507,423 | $5.87 | $2.98M | $75.00M | 1 | 2020-12-08 |
| 89bio, Inc. (ETNB) Delisted | Director | 2,002,221 | $14.84 | $29.71M | $53.60M | 1 | 2019-11-13 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 317,921 | $33.99 | $10.81M | $9.00M | 1 | 2018-07-24 |
| KALA | 10%+ Owner | 1,381 | $0.66 | $912 | $13.52M | 4 | 2018-02-12 |
| Adicet Bio, Inc. (TORC) Delisted | Director | 346,498 | — | — | $16.00M | 1 | 2018-01-30 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 135,333 | $0.69 | $93.4K | $0 | 1 | 2018-01-30 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 5,000,000 | $9.09 | $45.45M | $0 | 1 | 2017-06-15 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-12 | Turnstone Biologics Corp. (TSBX) Delisted | U | −6,198,530 | $0 | EDGAR |
| 2025-05-16 | NPCE | Sell (S) | −336,272 | -$5.33M | EDGAR |
| 2025-04-11 | CMPX | Sell (S) | −10,714,284 | -$17.04M | EDGAR |
| 2025-03-12 | IRON | Sell (S) | −1,249,536 | -$67.86M | EDGAR |
| 2024-08-23 | SPRY | Sell (S) | −2,606,046 | -$34.49M | EDGAR |
| 2024-05-20 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | U | −8,041,488 | $0 | EDGAR |
| 2024-01-25 | EWTX | Buy (P) | +1,363,635 | $15.00M | EDGAR |
| 2023-10-04 | NPCE | Sell (S) | −16,628 | -$150.9K | EDGAR |
| 2023-09-21 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | +459,363 | $0 | EDGAR |
| 2023-08-31 | SPRY | Buy (P) | +1,500,000 | $9.30M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.